Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Theodora Goulioti"'
Autor:
Carmela Caballero, Alexandre Irrthum, Theodora Goulioti, David Cameron, Larry Norton, Martine Piccart
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Despite recent advances in breast cancer research, we still know little about the mechanisms that lead to metastatic breast cancer (MBC). However, treatment options for patients have increased based on results of recent randomized clinical trials in
Externí odkaz:
https://doaj.org/article/436a2c1778be464e9164bd48409f3557
Autor:
Otto Metzger, Christina Herold, Coralie Poncet, Heidi De Swert, Jose Casas-Martin, Ann Partridge, Samia Guita, Lisa Carey, Eva Schumacher, Theodora Goulioti, Thomas Meyskens, Joseph Gannon, Khadija Benlhassan, Giovanna Rossi, Eleni Xenophontos, Amal Arahmani, Amylou C. Dueck, Gautier Paux, Etienne Brain, David A. Cameron
Publikováno v:
Cancer Research. 83:OT1-04
Background: About 30% of patients (pts) with hormone receptor (HR)-positive early breast cancer (EBC) on adjuvant aromatase inhibitor (AI) therapy discontinue due to toxicity with 22% of pts discontinuing during the first year (Henry et al. JCO 2012)
Autor:
Giuseppe Curigliano, Fabrice Andre, Nicholas C. Turner, Marie-Jeanne Pierrat, Sherene Loi, Sibylle Loibl, Theodora Goulioti, Malou Vicente, Elsemieke D. Scheepers, Laura Xuereb, Philippe L. Bedard, Philippe Aftimos, José Perez-Garcia, Amal Arahmani, Fergus Daly, Matteo Lambertini, Debora Fumagalli, Hatem A. Azim, Camille Poirot, Christine Campbell, Javier Cortes, Alex Pearson, Rina Hui
Supplementary Table S1. Treatment dose, duration, interruption and reduction. Supplementary Table S2A. Performance of the FGF23 ELISA, Kainos Laboratories Inc., cat# CY4000. Supplementary Table S2B. Concentration range of FGF23 in serum and plasma sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31c8f614a23932f5aed19174e8e3699a
https://doi.org/10.1158/1078-0432.22474223.v1
https://doi.org/10.1158/1078-0432.22474223.v1
Autor:
Giuseppe Curigliano, Fabrice Andre, Nicholas C. Turner, Marie-Jeanne Pierrat, Sherene Loi, Sibylle Loibl, Theodora Goulioti, Malou Vicente, Elsemieke D. Scheepers, Laura Xuereb, Philippe L. Bedard, Philippe Aftimos, José Perez-Garcia, Amal Arahmani, Fergus Daly, Matteo Lambertini, Debora Fumagalli, Hatem A. Azim, Camille Poirot, Christine Campbell, Javier Cortes, Alex Pearson, Rina Hui
Purpose:The FGFR1 gene is amplified in 14% of patients with HR+/HER2− breast cancer. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3, and PDGFRα/β, were assessed.Patients and Methods:Patients with HR+/HER2− metastatic breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32cf04ddf0d07a6cb6022d16c020f28e
https://doi.org/10.1158/1078-0432.c.6528728.v1
https://doi.org/10.1158/1078-0432.c.6528728.v1
Autor:
Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radisic, Michelle Naughton, Georg Pfeiler, Karen Gelmon, Ingrid Mayer, Daniel Egle, Gabriele Zoppoli, Tiffany Traina, Miguel Martin Jiménez, Silvia Antolin Novoa, Tufia Haddad, Arlene Chan, Alistair Edward Ring, Antonio Wolff, Jose JuanPonce Lorenzo, Dhanusha Sabanathan, Hal Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Meritxell Bellet-Ezquerra, Theodoros Foukakis, Yelena Novik, Gabor Rubovszky, Karoline Muehlbacher, Otto Metzger, Theodora Goulioti, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Dominik Hlauschek, Christian Fesl, Erica Mayer, Michael Gnant
Publikováno v:
Cancer Research. 82:P4-12
Background: As the development and use of oral anticancer agents increases, it is critical to understand patient adherence to both standard and investigational agents. The open label, phase 3 multicenter PALLAS trial investigates whether adding 2 yea
Publikováno v:
American Society of Clinical Oncology Educational Book. :231-239
Clinical trials cooperation is not a luxury; it is a necessity, now more than ever, first in light of the segmentation of tumors according to their molecular targets—which are being matched to an increasing number of competitive drugs—and second
Autor:
Gabriele Zoppoli, William Audeh, Theodora Goulioti, David Cameron, Iain R. Macpherson, Marco Colleoni, Antonino Musolino, Luis Manso, Audrey Mailliez, Evangelia Razis, Andrew Tutt, Virginie Adam, Peter Vuylsteke, John K. Erban, Michail Ignatiadis, Kai Yu Jen, István Láng, Bella Kaufman, Aafke H. Honkoop, Konstantinos Tryfonidis, Saskia Litière, Oskar T. Johannsson, Judith Balmaña, Olivier Tredan, Susan Ellard, Nicholas C. Turner, María José Juan-Fita, Lori J. Goldstein, C. Poncet
Publikováno v:
Clinical cancer research, 27 (20
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a1bfde4ac52e52c38e495f34c523cc
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
Autor:
Barbara Ruepp, Rupert Bartsch, Andrea Gombos, Frances M. Boyle, Giuseppe Viale, Anita Hiltbrunner, Thomas Bachelot, Martine Piccart-Gebhart, Caitlin Mahoney, Debora Fumagalli, Rina Hui, Theodora Goulioti, Fabrice Andre, Marco Colleoni, Carmen Comune, Magdelena Weber, Michelle Jenkins, Stefan Aebi, Stefania Andrighetto, Stamatina Fournarakou, Meredith M. Regan, Colleen King, Angelo Di Leo, Alan S. Coates, Rita Hui, Aron Goldhirsch, Mario Campone, Per Karlsson, Rolf A. Stahel, Vassiliki Karantza, Hui Huang, Laura Biganzoli, Hervé Bonnefoi, Sabrina Ribeli-Hofmann, Roswitha Kammler, Magdalena Sánchez-Hohl, Karolyn Scott, Patrick Schneier, Giuseppe Curigliano, Ingrid Kössler, Sherene Loi, Heather Findlay, Richard D. Gelber, Holly Shaw, Guy Jerusalem, Susan Fischer, Anita Giobbie-Hurder, Daniela Celotto, Manuela Rabaglio-Poretti, Rita Pfister, Michela Frapolli, Monica Greco, Adriana Gasca, Mark J. Smyth, Jaime A. Mejia, Karen N. Price, Heidi Roschitzki, Rudolf Maibach
Publikováno v:
The Lancet Oncology. 20:371-382
Summary Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tum
Autor:
Thomas Meyskens, Otto Metzger, Coralie Poncet, Theodora Goulioti, Eleni Xenophontos, Lisa A. Carey, Lei Wang, Giovanna Rossi, Leslie Gilham, Heidi De Swert, Jose Casas-Martin, Elham Attieh, Amal Arahmani, Laura De Meulemeester, Ann H. Partridge, Christina Isabella Herold, Gautier Paux, Amylou C. Dueck, Etienne Brain, David A. Cameron
Publikováno v:
Journal of Clinical Oncology. 40:TPS607-TPS607
TPS607 Background: There are currently limited treatment options for patients with HR+ EBC who have discontinued adjuvant treatment with aromatase inhibitors (AIs) due to treatment-related toxicity. Amcenestrant is an optimized oral selective estroge
Autor:
Catherine Lai, G. Viale, A Nguyen Duc, Heather L. McArthur, M.J. Piccart, M Ignatiadis, R. D. Gelber, Noam Pondé, Fergus Daly, Otto Metzger, Theodora Goulioti, E. de Azambuja, J-L Martinez, EP Winer, Andrew Bailey, Carter Dufrane, M Maetens, A. Bouhlel, V. Balta, V Van Dooren
Publikováno v:
Cancer Research. 79:OT3-05
Background: Triple negative breast cancer (TNBC) is a subtype with a high risk of relapse in the early disease setting. Because TNBC does not currently have specific targeted agents approved for use in the early setting it is treated primarily with c